Dr. Jay Avasarala, professor of neurology and director of UK’s Multiple Sclerosis Clinic, and co-authors, conducted a retrospective study in which they evaluated approximately 96.5 million enrollees in a database. Mark Cornelison l UK Photo LEXINGTON, Ky. (May 11, 2021) — Dr. Jay Avasarala, professor of neurology and director of the University of Kentucky’s Multiple Sclerosis Clinic, and co-authors, conducted a retrospective study in which they evaluated approximately 96.5 million enrollees in a database. More than 200,000 of the enrollees had inflammatory bowel disease (IBD). The research focused on looking at the effect of TNF-alpha inhibitors, biologic agents, used in IBD treatment on the probability of developing Multiple Sclerosis (MS).